Find Out Why the Life Sciences Industry’s Most Admired CHROs & HR Thought Leaders Are Clearing Their Schedules & Bringing Their Teams:
Over $100M in targeted cost savings over three years, delivered through an end-to-end R&D transformation across 2,500 employees in 35 countries in just 6–9 months.
CSL
Over $80M in cost avoidance over six years by eliminating reliance on retained search firms, while improving quality of hire, leadership readiness, and long-term retention.
Roche
Tens of millions of dollars in cost savings from centralizing L&D enterprise-wide, plus one set of leadership standards established across the business.
Merck & Co
TA annual operating costs reduced by approximately 50%, with millions redirected from low-impact programs to evidence-based interventions delivering measurably better talent outcomes.
Takeda
$4M in expense reduction through redesigned time-off policies, without compromising employee benefits or experience.
Sarah Cannon Research Institute
93%+ engagement, 100% employee advocacy, and zero regrettable turnover sustained through the first years of scaling.
Sionna Therapeutics
First-year culture transformation awareness scores above 4.2/5 across all regions, with measurable leadership accountability established.
Ferring Pharmaceuticals
Three INDs filed in one year, $413M raised (Series A) and $250M (Series B), and Great Place to Work® certification achieved — all built from zero people infrastructure.
Mirador
Seamless global reorganization impacting ~9,000 roles, improving spans of control, reducing duplication, and delivering a flatter, more agile organization with minimal business disruption.
Novo Nordisk
Manufacturing site scaled from start-up to nearly 600 employees, before evolving to support a population of over 2,000 — supported by a lean HRBP team.
BioMarin Pharmaceutical
Engagement scores retained above 90% and turnover below 5%, delivering higher fairness and greater cultural energy without expensive programs or large HR teams.
Grey Wolf Therapeutics
A 15-person HR team transformed into a single cohesive function, improving decision-making speed and reducing operational friction across a 550-employee organization over three years.
Arcus Biosciences
Scaled from fewer than 200 to 756+ employees globally in 4.5 years, enabling a full commercial build completed in one year.
Corcept Therapeutics
Reduced reliance on external hiring throughout a six-month talent-at-risk period during a prolonged acquisition, delivering exceptionally low regrettable attrition.
Blueprint Medicines
Sustained cross-level engagement over 18 months through the Stop the Swirl initiative, with measurable participation data and improved execution discipline across R&D.
Ultragenyx
Uplift across every culture survey question and a +7 point cumulative culture score increase post-RIF, demonstrating a direct link between values-led leadership and business readiness ahead of FDA approval.
Travere Therapeutics
Built two distinct sales forces and planned a 30–40% expansion of the US sales organization within a single year, through redesigned hiring for ambiguous, fast-evolving roles.
Alnylam Pharmaceuticals
Explore The 2026 Agenda
Hear real-world breakthroughs from the most senior biopharma people leaders across dedicated tracks of content for HR, TA, and L&D.
Partner With Us
Position your brand and services at the heart of the most innovative biopharma people leaders and 200+ VP-level decision-makers.
Join Your Peers
Be part of the most anticipated people and talent gathering in life sciences to build a resilient, integrated people strategy, and network that stays with you long-term.